Evaluation in nonhuman primates of vaccines against Ebola virus

Thomas W. Geisbert, Peter Pushko, Kevin Anderson, Jonathan Smith, Kelly J. Davis, Peter B. Jahrling

Research output: Contribution to journalReview article

196 Scopus citations

Abstract

Ebola virus (EBOV) causes acute hemorrhagic fever that is fatal in up to 90% of cases in both humans and nonhuman primates. No vaccines or treatments are available for human use. We evaluated the effects in nonhuman primates of vaccine strategies that had protected mice or guinea pigs from lethal EBOV infection. The following immunogens were used: RNA replicon particles derived from an attenuated strain of Venezuelan equine encephalitis virus (VEEV) expressing EBOV glycoprotein and nucleoprotein; recombinant Vaccinia virus expressing EBOV glycoprotein; liposomes containing lipid A and inactivated EBOV; and a concentrated, inactivated whole-virion preparation. None of these strategies successfully protected nonhuman primates from robust challenge with EBOV. The disease observed in primates differed from that in rodents, suggesting that rodent models of EBOV may not predict the efficacy of candidate vaccines in primates and that protection of primates may require different mechanisms.

Original languageEnglish (US)
Pages (from-to)503-507
Number of pages5
JournalEmerging infectious diseases
Volume8
Issue number5
DOIs
StatePublished - Jan 1 2002
Externally publishedYes

ASJC Scopus subject areas

  • Epidemiology
  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Evaluation in nonhuman primates of vaccines against Ebola virus'. Together they form a unique fingerprint.

  • Cite this

    Geisbert, T. W., Pushko, P., Anderson, K., Smith, J., Davis, K. J., & Jahrling, P. B. (2002). Evaluation in nonhuman primates of vaccines against Ebola virus. Emerging infectious diseases, 8(5), 503-507. https://doi.org/10.3201/eid0805.010284